Genelux (GNLX) Competitors $3.48 +0.17 (+5.14%) Closing price 04:00 PM EasternExtended Trading$3.48 +0.00 (+0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. EOLS, ALMS, CMPX, TECX, KOD, ETON, ARCT, RGNX, ITOS, and ESPRShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Evolus (EOLS), Alumis (ALMS), Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), Kodiak Sciences (KOD), Eton Pharmaceuticals (ETON), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Its Competitors Evolus Alumis Compass Therapeutics Tectonic Therapeutic Kodiak Sciences Eton Pharmaceuticals Arcturus Therapeutics REGENXBIO iTeos Therapeutics Esperion Therapeutics Genelux (NASDAQ:GNLX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Do insiders & institutionals believe in GNLX or EOLS? 37.3% of Genelux shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 8.8% of Genelux shares are held by company insiders. Comparatively, 5.9% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to GNLX or EOLS? In the previous week, Evolus had 6 more articles in the media than Genelux. MarketBeat recorded 9 mentions for Evolus and 3 mentions for Genelux. Evolus' average media sentiment score of 1.64 beat Genelux's score of 0.84 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, GNLX or EOLS? Genelux has a beta of -0.33, suggesting that its share price is 133% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Do analysts prefer GNLX or EOLS? Genelux presently has a consensus target price of $20.33, suggesting a potential upside of 484.29%. Evolus has a consensus target price of $21.25, suggesting a potential upside of 182.96%. Given Genelux's stronger consensus rating and higher probable upside, equities research analysts clearly believe Genelux is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Evolus 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is GNLX or EOLS more profitable? Genelux has a net margin of 0.00% compared to Evolus' net margin of -22.31%. Genelux's return on equity of -107.47% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -107.47% -83.14% Evolus -22.31%-759.04%-24.63% Which has better earnings & valuation, GNLX or EOLS? Genelux has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$10K13,143.96-$29.87M-$0.86-4.05Evolus$266.27M1.82-$50.42M-$0.98-7.66 SummaryGenelux beats Evolus on 9 of the 16 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.03M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-4.0520.8978.4326.42Price / Sales13,143.96458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book4.589.9310.916.06Net Income-$29.87M-$53.38M$3.29B$266.28M7 Day Performance-1.42%0.05%0.01%-0.76%1 Month Performance-0.85%7.08%7.06%3.83%1 Year Performance46.84%11.92%50.09%24.39% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.2333 of 5 stars$3.48+5.1%$20.33+484.3%+59.1%$125.03M$10K-4.0510News CoverageEOLSEvolus4.5346 of 5 stars$7.63+1.5%$21.25+178.5%-52.6%$493.55M$266.27M-7.79170News CoveragePositive NewsShort Interest ↓ALMSAlumis2.5689 of 5 stars$4.64-1.3%$20.17+334.6%-61.6%$482.86MN/A0.00N/ACMPXCompass Therapeutics2.691 of 5 stars$3.49flat$12.89+269.3%+123.2%$482.61M$850K-7.7620News CoveragePositive NewsTECXTectonic Therapeutic2.7759 of 5 stars$25.54-0.1%$80.33+214.5%-14.9%$477.91MN/A-6.32120News CoveragePositive NewsAnalyst ForecastKODKodiak Sciences3.8189 of 5 stars$9.04+0.8%$11.75+30.0%+254.1%$477.51MN/A-2.3890Positive NewsETONEton Pharmaceuticals2.579 of 5 stars$17.31+0.2%$29.67+71.4%+279.3%$464.21M$39.01M-108.1920News CoveragePositive NewsARCTArcturus Therapeutics3.6569 of 5 stars$17.01-1.7%$50.57+197.3%-11.3%$461.90M$152.31M-7.63180News CoveragePositive NewsAnalyst ForecastRGNXREGENXBIO4.3899 of 5 stars$8.93-0.9%$28.38+217.7%-13.1%$451.09M$83.33M-2.60370News CoverageITOSiTeos Therapeutics3.5147 of 5 stars$10.15flat$15.50+52.7%N/A$448.68M$35M-2.1790News CoveragePositive NewsShort Interest ↓ESPREsperion Therapeutics3.8892 of 5 stars$2.22+0.5%$7.00+215.3%+32.8%$447.60M$332.31M-4.53200Options Volume Related Companies and Tools Related Companies Evolus Alternatives Alumis Alternatives Compass Therapeutics Alternatives Tectonic Therapeutic Alternatives Kodiak Sciences Alternatives Eton Pharmaceuticals Alternatives Arcturus Therapeutics Alternatives REGENXBIO Alternatives iTeos Therapeutics Alternatives Esperion Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredNewegg (NEGG) Earns BULLISH Rating – Up 934%The last time he shared a free AI stock pick like this, it soared 100%.Chaikin Analytics | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNLX Stock Alerts